Harvey B. Sarnat

Hemimegalencephaly: Part 2. Neuropathology Suggests a Disorder of Cellular Lineage

Cerebral tissue from hemispherectomy in three children (two 4-month-old girls and one 4-year-old boy) with hemimegalencephaly was studied using histochemical and immunocytochemical markers of neuronal and glial maturation and identity. Histologic abnormalities of cellular growth and cytomorphology, including “balloon cells,” were present in both gray and white matter, in addition to disorganized tissue architecture. Cells in the mitotic cycle were absent. Many hypertrophic, atypical cells with enlarged processes exhibited mixed or ambiguous lineage, with immunoreactivity for both glial (glial fibrillary acidic protein [GFAP]; S-100β) and neuronal proteins (microtubule-associated protein 2 [MAP2], neuronal nuclear antigen, chromogranin A, and neurofilament protein [NFP]). Strong vimentin reactivity was present in neurons, as well as glial cells and cells of mixed lineage, suggesting incomplete maturation. Synaptophysin-reactive axons terminated on a minority of balloon cells and on most heterotopic single neurons in white matter, confirmed by electron microscopy, demonstrating that single heterotopic neurons are not synaptically “isolated,” as they may appear; thus, they are capable of contributing to epilepsy. Oligodendrocytes are the least affected cells, at least in some cases. The findings are reminiscent of the hamartomas of tuberous sclerosis. We conclude that hemimegalencephaly is a primary disorder of neuroepithelial lineage and cellular growth. A migratory disturbance contributes to disorderly tissue architecture but is secondary. No pathologic difference is detected between isolated and syndromic forms of hemimegalencephaly. (J Child Neurol 2003;18:776—785).

Integrative classification of morphology and molecular genetics in central nervous system malformations

We propose a scheme to classify central nervous system (CNS) malformations that integrates morphology and genetics by using patterns of genetic expression as its basis. The precise genetic mutations are not necessary to know in all cases. The premises of this classification are (1) genetic expression in the neural tube follows gradients in the axes that are established at the time of gastrulation: vertical (dorsoventral and ventrodorsal); rostrocaudal; mediolateral. (2) Overexpression in one of these gradients generally results in duplication or hyperplasia of structures, or ectopic segmental (i.e., neuromeric) expression. (3) Underexpression in a gradient generally results in hypoplasia, noncleavage in the midline of paired structures or segmental deletion of neuromeres. These gradients may also affect the formation and migration of neural crest tissue, affecting non‐neural structures such as the face in the case of the mesencephalic neural crest, or induction of paraxial mesodermal in the posterior fossa. Additional criteria of the new classification allow for other genetic influences on developmental processes, such as cellular lineage, exemplified by tuberous sclerosis, and hemimegalencephaly. It is essential that the CNS be considered as a whole and classification not be regionalized, as to the cerebral cortex, because the limit of the rostrocaudal gradient may account for variability in clinical manifestations.

Regional ependymal upregulation of vimentin in Chiari II malformation, aqueductal stenosis, and hydromyelia.

Vimentin, glial fibrillary acidic protein (GFAP) and S-100 β protein were studied by immunocytochemistry in the ependyma of patients with Chiari II malformations, congenital aqueductal stenosis, and hydromyelia. Paraffin sections of brains and spinal cords of 16 patients were examined, 14 with Chiari II malformations, most with aqueductal stenosis and/or hydromyelia as associated features, and 2 patients with congenital aqueductal stenosis without Chiari malformation. Patients ranged in age from 20-wk gestation to 48 years. The results demonstrated: 1) in the fetus and young infant with Chiari II malformations, congenital aqueductal stenosis, and hydromyelia, vimentin is focally upregulated in the ependyma only in areas of dysgenesis and not in the ependyma throughout the ventricular system; 2) GFAP and S-100β protein are not coexpressed, indicating that the selective upregulation of vimentin is not simple maturational delay; 3) vimentin upregulation also is seen in the ependymal remnants of the congenital atretic cerebral aqueduct, not associated with Chiari malformation; 4) in the older child and adult with Chiari II malformation, vimentin overexpression in the ependyma becomes more generalized in the lateral ventricles as well, hence evolves into a nonspecific upregulation. The interpretation from these findings leads to speculation that it is unlikely that ependymal vimentin is directly involved in the pathogenesis of Chiari II malformation, but may reflect a secondary upregulation due to defective expression of another gene. This gene may be one of rhombomeric segmentation that also plays a role in defective programming of the paraxial mesoderm for the basioccipital and supraoccipital bones resulting in a small posterior fossa. This interpretation supports the hypothesis of a molecular genetic defect, rather than a mechanical cause, as the etiology of the Chiari II malformation.

DSCAM: an endogenous promoter drives expression in the developing CNS and neural crest

The development of central nervous system (CNS) neuronal networks involves processes including neuroblast migration, axonal pathfinding, and synaptogenesis. To evaluate the role of the axonal guidance molecule DSCAM in CNS connectivity, we generated a lacZ reporter construct, Pr1.8-betagal, containing a 1.8kb fragment of the human DSCAM promoter region, and analyzed its expression in four E12.5 transgenic mouse embryos. We found that Pr1.8-betagal drives lacZ expression in the choroid plexus and roof of the fourth ventricle, the floor plate of the fourth ventricle, pons and medulla oblongata, and the eye, limb buds, and dorsal root ganglion. This recapitulates a subset of DSCAM expression as demonstrated by in situ hybridization, supporting this 1.8kb fragment as a component of the endogenous DSCAM promoter. The Pr1.8-betagal expression pattern supports a role for DSCAM in CNS development, providing an endogenous promoter to investigate the contribution of DSCAM to Down syndrome neural defects.

Commentary by Series Editor

Received Feb 27, 2002. Accepted for publication March 14, 2002. From the Department of Pediatrics (Neurology) and Pathology (Neuropathology), Cedars-Sinai Medical Center, Los Angeles, CA. Address correspondence to Dr Harvey B. Sarnat, Department of Pediatrics, Cedars-Sinai Medical Center, 4221 North Tower, 8700 Beverly Blvd, Los Angeles, CA 90048. Hemimegalencephaly has been one of the most enigmatic of the many cerebral malformations because, unlike failure of neural tube closure, arrested neuroblast migration, or lack of differentiation of certain structures of the brain, this asymmetric dysgenesis cannot be identified as a disturbance or maturational arrest in any normal stage of development. In this article, and the companion article on the pathology of hemimegalencephaly that will follow in the coming months, Dr Flores-Sarnat not only presents an exhaustive review of the clinical, imaging, and neurophysiologic features of hemimegalencephaly, from both the literature and her own clinical experience, but also proposes

Marin-Garcia et al: Striated Muscle Mitochondrial Phenotype: Probing striated muscle mitochondrial phenotype in neuromuscular disorders

Multisystemic disorders with predominantly neurologic manifestations often present with mitochondrial abnormalities in striated muscle biopsies. Decreased respiratory complex activities and abnormalities in mitochondrial structure and DNA constitute the spectrum of mitochondrial changes used as diagnostic and prognostic indicators in patients with neuromuscular disorders. This study assessed mitochondrial defects present in a cohort of 154 young patients to determine diagnostic efficiency and probe the relationship of mitochondrial to clinical phenotype. Striated muscle biopsies were analyzed for mitochondrial structure and number, levels of enzyme activities of complex I-V and citrate synthase, mitochondrial DNA and specific mitochondrial DNA deletions, and presence of 15 pathogenic mitochondrial DNA point mutations. Reduced complex I, III, IV, and V activities were the most ubiquitous finding, with complex III most commonly affected. Mitochondrial structural defects (39%) included changes in mitochondria sizes/shapes and number and aberrant cristae formation. Mitochondrial DNA deletions were evident in 15 patients, three displayed mitochondrial DNA depletion, and only two harbored pathogenic point mutations. Reductions in specific enzyme activities may be the most sensitive diagnostic indicator, whereas defects in ultrastructure and mitochondrial DNA integrity were frequently accompanied by the full spectrum of mitochondrial abnormalities. Some phenotypes displayed specific mitochondrial abnormalities; however, most clinical phenotypes displayed little specificity with regard to mitochondrial phenotype.

Severe mitochondrial cytopathy with complete a-v block, peo, and mtDNA deletions

We describe a 17-year-old male with neurologic and cardiovascular disorders characterized by complete atrioventricular block and a mitochondrial cytopathy with clinical, structural, biochemical, and molecular features shared by chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. The patients manifestations included progressive external ophthalmoplegia, bilateral ptosis, muscle weakness, delayed development, and progressive hearing loss with multiple mitochondrial DNA deletions, including an abundant 11-kb novel deletion and reduced specific activities of respiratory complexes I, III, and IV present in skeletal muscle. Ultrastructural analysis of biopsied muscle revealed a heterogenous mixture of normal and abnormal mitochondria with unusual cristae. This unique mitochondrial DNA deletion, which eliminates the origin of mitochondrial DNA replication for the light strand, may be responsible for generating an intermediate clinical phenotype.